LAUSR

Use of technology in the management of type 1 diabetes (T1D) can help patients in achieving optimal glycemic control, decreasing the rates of diabetes complications. The most advanced Automated Insulin Delivery (AID) systems, referred as hybrid closed loop systems (HCL), combine the use of real-time continuous glucose monitoring (CGM) with an algorithm that automatically and continuously adjusts the rate of subcutaneous insulin delivery via an insulin pump in response to glycemic trends [1]. Mealtimes boluses are still manual, requiring patients to manually input information about carbohydrates count, preferably 10–15 min before meals. This is the reason why the current AID systems are considered “hybrid closed loop”. The Medtronic Minimed® 780G system is an Advanced Hybrid Closed-Loop system (AHCL) that includes the most advanced Medtronic SmartGuard algorithm with individualized target set points of 5.6 mmol/L (100 mg/dl)–6.1 mmol/L (110 mg/dl)–6.7 mmol/L (120 mg/dl) and automated correction boluses enabled every five minutes. The automated corrections should mitigate postprandial hyperglycemia due to carbohydrate underestimation or late/missed boluses [2, 3]. AHCL therapy is now available in clinical practice, however, there is limited research on how patients manage and deal with these AID systems and on how to educate patients and caregivers on this new therapy.